Cosmetic or dermatological composition and use thereof

Abstract

Some embodiments are directed to a cosmetic composition including at least one extract of Jania rubens and at least one extract of everlasting. Some embodiments are also directed to the cosmetic use of a composition including at least one extract of Jania rubens and at least one extract of everlasting. Some embodiments are also directed to a non-therapeutic anti-ageing cosmetic treatment and/or the protection of the skin against external attacks, using a cosmetic composition including at least one extract of Jania rubens and at least one extract of everlasting. Some embodiments particularly apply to the cosmetic and/or dermatological fields.

Claims

1. A cosmetic composition, comprising: at least one extract of slender-beaded coral weed, an essential oil of everlasting, and at least one aqueous extract of everlasting and/or an oily extract of everlasting, wherein the concentration of extract of slender-beaded coral weed is from 0.001% to 5% by weight relative to the total weight of the composition.

2. The composition as claimed in claim 1, wherein the extract of slender-beaded coral weed is chosen from the group comprising a water-soluble extract of slender-beaded coral weed, a liposoluble extract of slender-beaded coral weed or a mixture thereof.

3. The composition as claimed in claim 2, wherein the concentration of extract of everlasting is from 0.001% to 10% by weight relative to the total weight of the composition.

4. The composition as claimed in claim 2, wherein the extract of everlasting is an extract of Helichrysum italicum.

5. The composition as claimed in claim 1, wherein the concentration of extract of everlasting is from 0.001% to 10% by weight relative to the total weight of the composition.

6. The composition as claimed in claim 1, wherein the extract of everlasting is an extract of Helichrysum italicum.

7. The composition as claimed in claim 1, wherein the extract of slender-beaded coral weed is an extract of Jania rubens.

8. The composition as claimed in claim 1, wherein the composition is in a form chosen from a cream, a serum, a milk, a gel, a lotion, an ointment, an oil, a balm and a mask.

9. A method of using the composition as claimed in claim 1 for nontherapeutic antiaging cosmetic treatment, comprising: applying the composition to skin.

10. A method of using the composition as claimed in claim 1 for nontherapeutic cosmetic treatment, comprising: applying the composition to skin for treating aging of the skin, wrinkles and fine lines, loss of skin firmness, loss of skin elasticity and dry skin.

11. A method of using the composition as claimed in claim 1 for nontherapeutic cosmetic treatment, comprising: applying at least one extract of slender-beaded coral weed and at least one extract of everlasting to skin for protecting the skin against external attack.

12. A method of using the composition as claimed in claim 1, comprising: applying at least one extract of slender-beaded coral weed and at least one extract of everlasting to skin in a nontherapeutic cosmetic treatment of aging of the skin, wrinkles and fine lines, loss of firmness, loss of elasticity and/or dry skin.

13. A method of using the composition as claimed in claim 1 for a nontherapeutic cosmetic treatment, comprising: applying the composition to the skin for protecting the skin against external attack.

14. A nontherapeutic cosmetic treatment process, comprising: applying the cosmetic composition as claimed in claim 1 to skin.

15. A cosmetic care kit for using the composition of claim 1 in a nontherapeutic cosmetic treatment for protecting skin against external attack, the kit comprising: the composition of claim 1, and a notice for use.

Description

EXAMPLES

Example 1: Example of a Facial Care Composition (Cream)

(1) A base composition was prepared according to the following process: the various ingredients were prepared beforehand and weighed out, glycerol was introduced into the water and mixed at 1500 rpm and heated to 80 C., the gelling agent was dispersed in this mixture with stirring at 1500 rpm until dissolved. The oily phase prepared beforehand by mixing, for example, the emulsifying agent, the hard fatty substances, the caprylic capric triglycerides, the ester and the plant oils, with heating, at 80 C., until a homogeneous mixture was obtained, was introduced with stirring at a speed of 1500 rpm until a cream was obtained, which was then cooled to 40 C. with stirring at 1500 rpm. The active agents, for example the trace elements, the vitamin C derivative, and also the fragrance, the preserving agents and the pH regulator, were then added.

(2) Table 1 below summarizes the composition of the cream.

(3) TABLE-US-00001 TABLE 1 base composition for the face (cream) Amount as weight % relative to the total weight of the Ingredients composition Emulsifying agent 1 to 10% Moisturizing agents 1 to 15% (glycerol) Hard fatty substances 1 to 5% Caprylic capric triglycerides 5 to 25% Ester 10-20% Plant oils 1-5% Gelling agent 1-5% Fragrance QSP Water QSP Preserving agents QSP

(4) Starting with this base composition, for facial care, various compositions in accordance with some embodiments were manufactured by adding an extract of slender-beaded coral weed and an extract of everlasting in various amounts.

(5) The extract of slender-beaded coral weed was a water-glycerol extract (50/50 v/v) of Janis rubens sold by the company CODIF under the commercial reference Actiporine 8G.

(6) The extract of everlasting was an essential oil of everlasting obtained by hydrodistillation and provided by the companies TEPPE ROSSE, STEPHAN FRANCISCI, GAEC de 1'ASTRATELLA or a mixture of two or three of these oils.

(7) The extract of everlasting was a biological aqueous extract of Corsican everlasting obtained by extraction and provided by the company Greentech.

(8) The extract of everlasting was an oily extract obtained by ultrasound-assisted microwave oily extraction and provided by the company Olos.

(9) The various ingredients were dispersed using a laboratory mixer such as a bench stirrer.

(10) Starting with the base composition, compositions were prepared including: 0.1; 0.05; 0.03; 0.02; 0.01% by weight of oily extract of everlasting relative to the total weight of each composition 0.5; 0.2; 0.1; 0.05; 0.02; 0.01% by weight of aqueous extract of everlasting relative to the total weight of each composition 0.2; 0.1; 0.05; 0.02; 0.01% by weight of essential oil of everlasting relative to the total weight of each composition 3; 2; 1; 0.5; 0.1% by weight of slender-beaded coral weed relative to the total weight of each composition.

(11) The values of fragrance, preserving agent and water then being adjusted as indicated in table 1 above.

(12) The weight percentages of extracts of everlasting and extract of slender-beaded coral weed are indicated in table 2 below.

(13) TABLE-US-00002 TABLE 2 weight percentage of oily extract of everlasting, of aqueous extract of everlasting, of essential oil of everlasting and of extract of slender- beaded coral weed relative to the total weight of the composition Weight % of aqueous Weight % of Weight % of Weight % of extract of oily aqueous essential slender- extract of extract of oil of beaded coral everlasting everlasting everlasting weed relative to relative to relative to relative to the weight the weight the weight the weight of the of the of the of the composition composition composition composition Composition (%) (%) (%) (%) No. 1 0.01 0.5 0.1 3 No. 2 0.02 0.01 0.05 1 No. 3 0.01 0.2 0.01 2 No. 4 0.03 0.1 0.1 0.5 No. 5 0.1 0.01 0.05 3 No. 6 0.03 0.1 0.05 2 No. 7 0.01 0.01 0.2 0.1 No. 8 0.02 0.02 0.1 1 No. 9 0.03 0.01 0.05 2 No. 10 0.1 0.1 0.1 3 No. 11 0.05 0.05 0.02 0.5

Example 2: Effect on the Expression of Skin Genes of an Extract of Slender-Beaded Coral Weed, of Essential Oil of Everlasting and of a Mixture Including an Extract of Slender-Beaded Coral Weed and of Essential Oil of Everlasting

(14) For the extract of slender-beaded coral weed, it was a water-glycerol extract (50/50 v/v) of Jania rubens sold by the company CODIF under the commercial reference Actiporine 8G.

(15) For the essential oil of everlasting, it was an essential oil obtained by hydrodistillation and provided by the companies TEPPE ROSSE, STEPHAN FRANCISCI, GAEC de l'ASTRATELLA or a mixture of two or three of these oils.

(16) The transcriptome is all of the messenger RNAs derived from the expression of part of the genome in a given tissue or cell type. Characterization and quantification of the transcriptome make it possible to identify the genes regulated under particular conditions, to determine the mechanisms for regulating these genes and to define the expression networks or activation pathways of these genes. One of the techniques used to simultaneously measure the level of expression of a large number of different messenger RNAs is that of the DNA microarray. DNA microarrays make it possible to very rapidly measure and visualize the differences in expression on the scale of a whole genome.

(17) 1. Materials and Methods

(18) The extract of slender-beaded coral weed, the essential oil of everlasting or the combination of the two extracts were placed in contact with skin explants maintained under survival conditions. The essential oil of everlasting was dissolved at 10% in dimethyl sulfoxide (DMSO) before being applied to the culture medium. The extract of slender-beaded coral weed was, for its part, diluted directly in the same culture medium.

(19) 4 skin explants originating from an abdominal plasty of a 62 year old patient were incubated independently. They were incubated in the presence of the extract of slender-beaded coral weed, of the essential oil of everlasting or of the combination thereof for 24 hours in a skin culture medium from the company Biopredic at 37 C. containing 5% CO.sub.2 under a humid atmosphere (98%) at the air-liquid interface. 4 skin explants that were untreated or treated with the solvent DMSO at 1% were incubated under the same conditions.

(20) Table 3 below summarizes the concentrations applied for each composition.

(21) TABLE-US-00003 TABLE 3 concentration applied for each composition Composition Percentage (%) Extract of slender-beaded coral 0.2 weed Essential oil of everlasting 0.1 Extract of slender-beaded coral 0.2 weed and 0.1 essential oil of everlasting
Extraction of the Total RNAs

(22) After incubation, the skin explants were ground in the buffer recommended by the manufacturer of the RNeasy mini kit (Qiagen, Hilden, Germany) and the total RNAs were then extracted using this same kit. The total RNAs were quantified and their quality was then checked using the BIOanalyzer 2100 with the RNA 6000 Nano LabChip Kit (Agilent Technologies, Santa Clara, USA).

(23) Measurement of the Gene Expression on an Oligonucleotide Microarray and Data Acquisition:

(24) 60 mer oligonucleotide microarrays on 13 glass slides, SurePrint G3 Human Gene Expression 860 K v2 Microarray (G4851B, Agilent Technologies, Santa Clara, USA) were used for the analysis of the gene expression (SurePrint G3 Human Gene Expression 860 K v2, Agilent Technologies, Santa Clara, USA).

(25) Documentation and the full experimental protocol are available on the Agilent Technologies website [32].

(26) Briefly, reverse transcription and amplification of the total RNAs into cDNA and then into cRNA and labeling thereof with cyanine 3 are performed using the Low Input Quick Amp Labeling Kit (Agilent Technologies). Purification of the cRNAs was performed using the RNeasy mini kit (Qiagen, Hilden, Germany) and hybridization with the Microarray hybridization chamber kit (Agilent Technologies, Santa Clara, USA). The microarrays were then scanned using the SureScan scanner (Agilent Technologies, Santa Clara, USA) and the Scan control software (Agilent Technologies, Santa Clara, USA). The scanned images were then extracted and normalized with the Feature Extraction software (Agilent Technologies, Santa Clara, USA).

(27) Statistical analysis of the data was performed using the GeneSpring GX 13 software (Agilent Technologies, Santa Clara, USA).

(28) The Ingenuity Pathways Analysis software (Ingenuity Pathway Analysis (IPA), Ingenuity Systems, Redwood City, Calif., USAhttp://www.ingenuity.com) was then used to analyze and predict the state of activation of the biological pathways modulated with the extract of slender-beaded coral weed, the essential oil of everlasting or the combination thereof.

(29) For each treatment condition, 4 independent labeling experiments were performed (i.e. 4 oligonucleotide microarrays per condition, corresponding to the 4 skin explants treated independently for each condition) to increase the data reproducibility.

(30) The genes expressed by the treated skin explants were considered as being induced or inhibited if their level of differential expression was greater by a factor of 2 compared with those of the control explants. The untreated explants served as control for the condition treated with the extract of slender-beaded coral weed and the explants treated with the 1% DMSO solvent served as control for the condition treated with the essential oil of everlasting or the combination of the extract of slender-beaded coral weed and the essential oil of everlasting in combination. A moderated T-test corrected for the level of false positives was applied with the Benjamini & Hochberg procedure [33] by the GeneSpring software so as to calculate the statistical difference in gene expression between the untreated explants or the explants treated with the DMSO solvent and the explants treated with the active agents or the combination thereof. The genes whose p-value was less than or equal to 0.05 were considered as differentially expressed.

(31) These genes were then analyzed with the Ingenuity Pathways Analysis software. This software allows functional analysis of the genes regulated under the various treatment conditions, analysis of the signaling pathways in which these genes are inscribed and analysis of the regulators upstream of these pathways. A Z-score was calculated by the software relative to the significantly regulated genes. A Z-score >2 or <2 indicates within a 99% confidence interval that the induced or suppressed biological pathways are not induced or suppressed purely by chance, but quite specifically.

(32) TABLE-US-00004 TABLE 4 Z-score of the pathway for the differentiation of epidermal cells in response to treatment of the skin explants with the extract of slender-beaded coral weed, the essential oil of everlasting and the combination thereof Extract of Extract of Everlasting slender-beaded slender-beaded essential oil coral weed and coral weed (EO) everlasting EO Differentiation 1.948 2.398 of the epidermal cells

(33) The table below presents the difference in expression of the genes involved in the differentiation of the epidermal cells following treatment of the skin explants with the extract of slender-beaded coral weed, the essential oil of everlasting and the combination thereof.

(34) TABLE-US-00005 TABLE 5 difference in expression as a function of incubation with an extract of slender-beaded coral weed, an essential oil of everlasting or a combination of extract of slender-beaded coral weed and an essential oil of everlasting STATUS in the study: Expression relative to the untreated control or to the solvent control Slender- beaded Slender-beaded GENES Genbank coral Everlasting coral weed and Symbol Name Accession weed EO everlasting EO AURKB aurora kinase B NM_004217 3.07 4.89 CDK1 cyclin-dependent NM_001786 2.40 2.92 kinase 1 EGF epidermal growth NM_001963 2.21 factor FLG Filaggrin NM_002016 2.03 FLG2 Filaggrin family NM_001014342 2.24 member 2 FOXM1 forkhead box M1 NM_202002 2.75 2.79 FOXN1 forkhead box N1 NM_003593 2.09 GAK cyclin G associated AK131464 2.35 kinase GLI2 GLI family zinc finger 2 NM_005270 2.04 HDAC2 histone deacetylase 2 NM_001527 2.05 2.28 HGF hepatocyte growth NM_001010934 4.29 factor (hepapoietin A; scatter factor) HOXA7 homeobox A7 NM_006896 2.64 IL20 interleukin 20 NM_018724 2.51 2.54 LATS2 large tumor NM_014572 2.11 suppressor kinase 2 MAPK8 mitogen-activated NM_001278547 2.45 2.68 protein kinase 8 PPARD peroxisome NM_006238 2.85 3.06 proliferator-activated receptor delta TNF tumor necrosis factor NM_000594 3.68 TNFSF10 tumor necrosis factor NM_003810 8.80 12.02 (ligand) superfamily, member 10 TNFSF12 tumor necrosis factor NM_003809 2.11 2.16 (ligand) superfamily, member 12 TP63 tumor protein p63 NM_003722 3.03 3.39 VDR vitamin D (1,25- NM_001017535 2.37 2.49 dihydroxyvitamin D3) receptor WNT16 wingless-type MMTV NM_057168 4.21 7.57 integration site family, member 16

(35) In the abovementioned table, the numerical value represents the stimulation or inhibition factor relative to untreated skin, db EST is a database collating the gene reference and also its sequence corresponding to the gene spotted on the 60 mer oligonucleotide microarrays on 13 glass slides, SurePrint G3 Human Gene Expression 860 K v2 Microarray (G4851B, Agilent Technologies, Santa Clara, USA), and the absence of gene regulation.

(36) The results obtained demonstrate that treatment of the explants by the combination of the extract of slender-beaded coral weed and of the essential oil of everlasting induces an increase in the differentiation of the epidermal cells with a Z-score of 2.398 whereas the essential oil of everlasting alone only induces a Z-score of 1.948, which is insignificant, and that the extract of slender-beaded coral weed alone does not induce this pathway.

(37) Thus, as demonstrated above, an example of a composition according to some embodiments including a mixture of at least one extract of slender-beaded coral weed and of essential oil of everlasting advantageously makes it possible, especially by increasing the differentiation of the epidermal cells, to reinforce the barrier function of the skin, to maintain better moisturization, to stimulate the skin's defenses and to enhance or improve the surface quality of the skin.

(38) As demonstrated in the table, the mixture including the extract of slender-beaded coral weed and the essential oil of everlasting advantageously makes it possible to stimulate the expression of the genes coding for filaggrin and for filaggrin 2. These two proteins play a fundamental role in maintaining the skin moisturization. They are co-located in the keratohyalin granules of the granulous keratinocytes and in the cytoplasmic matrix of the corneocytes. When filaggrin is degraded to amino acids, it partly constitutes the skin's natural moisturizing factor (NMF) [21]. The exact role of filaggrin 2 has not yet been discovered, but it appears to be similar to that of filaggrin and is of importance for the correct functioning of cornification and for the constitution of a functional stratum corneum [34].

(39) The mixture including the extract of slender-beaded coral weed and the essential oil of everlasting also advantageously makes it possible to inhibit expression of the gene coding for HOXA7. Overexpression of this gene is known to reduce the induction of transglutaminase 1 and expression of HOXA7 is inversely correlated to keratinocyte differentiation which is involved in the correct functioning and the formation of the epidermal barrier [35].

(40) Furthermore, the mixture including the extract of slender-beaded coral weed and the essential oil of everlasting also advantageously makes it possible to induce the gene coding for cyclin G associated kinase (GAK) which is known to be involved in the formation of the epidermal barrier. Specifically, mice in which the GAK gene has been specifically deleted in the skin die at birth by desiccation because their epidermal barrier is defective [36] due to a defect in the differentiation process such that the absence of multiple layers which normally form the epidermis and the stratum corneum does not develop correctly.

(41) Similarly, inhibition of the gene coding for tumor necrosis factor alpha (TNF-) by the mixture of the aqueous extract and of the essential oil of everlasting leads to a barrier function that is advantageously reinforced by the mixture of these two active agents. Specifically, the proteins filaggrin and loricrin are known to be inhibited by TNF-. The mixture of the extract of slender-beaded coral weed and of essential oil of everlasting, by advantageously inhibiting TNF-, allows the expression of loricrin and filaggrin and thus reinforcement of the epidermal barrier.

(42) Moreover, the epidermal growth factor (EGF) and hepatocytic growth factor (HGF) are induced only in the presence of the mixture of the extract of slender-beaded coral weed and of the essential oil of everlasting. These growth factors are essential for keratinocyte proliferation and their induction increases epidermal turnover. Decreasing the proliferative capacity of keratinocytes participates in the thinning of the epidermis in the course of aging. Thus, treatment with the mixture of the two extracts synergistically restores this thickness [37]. The other genes also regulated by the mixture of the extract of slender-beaded coral weed and of the essential oil of everlasting (table 5) also contribute toward the formation of the epidermal barrier or epidermal turnover.

(43) This example clearly demonstrates by ex vivo transcriptome analysis with DNA microarrays that the composition of some embodiments makes it possible to stimulate genes involved in particular in the differentiation of the epidermal cells.

(44) This example also clearly demonstrates that a composition including an extract of slender-beaded coral weed and an extract of everlasting advantageously makes it possible to stimulate the epidermal barrier functioning and/or function, making it possible in particular to protect the skin against external attack, to maintain/increase skin moisturization, to prevent and/or treat aging of the skin, for example by conserving and/or restoring the thickness of the epidermis, to enhance or improve the surface quality of the skin and thus to have a complexion that is more radiant due to better light reflection.

Example 3: Test of Use of an Example of a Cosmetic Composition According to Some Embodiments and Evaluation of the Cosmetic Qualities of the Composition

(45) In order to validate the effects of an example of a composition according to some embodiments, a use test was performed on an independent panel of female volunteers.

(46) The use test was conducted on a panel of 54 volunteers between 42 and 65 years old (average age of 56), presenting with wrinkles and fine lines, a lack of radiance and a lack of skin firmness on the skin of the face and neck.

(47) After breathing in the fragrance, the composition was applied twice a day morning and evening for 28 days in a small dose using a spatula, by a smoothing movement from the interior to the exterior of the face and neck, which were cleansed beforehand.

(48) The composition used included the compounds indicated in table 1 and 0.03% by weight of oily extract of everlasting, 0.1% by weight of aqueous extract of everlasting, 0.05% by weight of essential oil of everlasting and 2% by weight of aqueous extract of slender-beaded coral weed relative to the total weight of the composition.

(49) TABLE-US-00006 TABLE 6 overall judgment of the composition General assessment of the product On application The texture is silky 93% The texture changes in the course of 76% application The product melts on the skin 78% Immediately after the first application The skin is nourished 94% The skin is comforted 93% The skin is supple 91% The skin appears uncreased 70% The skin is more tonic 70% After 28 days of use The skin is intensely nourished 83% The product offers a real sensation of 83% comfort The skin is more supple 81% The lines appear redefined 78% The skin is firmer 61% The skin is more elastic 69%

(50) As demonstrated in table 6, an example of a composition according to some embodiments including 0.03% by weight of oily extract of everlasting, 0.1% by weight of aqueous extract of everlasting, 0.05% by weight of essential oil of everlasting and 2% by weight of aqueous extract of slender-beaded coral weed relative to the total weight of the composition was thus considered as effective. In particular, as demonstrated, an example of a composition according to some embodiments makes it possible to treat the signs of aging, especially an enhancement or improvement in skin moisturization, the treatment of wrinkles and fine lines, the enhancement or improvement in the elasticity and firmness of the skin. As demonstrated, the composition advantageously allows treatment immediately after application and over time.

Example 4: Test of Use of an Example of a Cosmetic Composition According to Some Embodiments and Evaluation of the Cosmetic Qualities of the Composition

(51) The use test was conducted on a panel of 35 female asiatic volunteers between 40 and 65 years old (54.6 years old on average) representing all skin types, for example dry, normal, combination and greasy skin. They had dull skin, a light complexion with the presence of pigmentation marks, namely with a density defined according to the Aging Atlas of grade2, and at least one well-defined mark on the cheek, for example from 2.5 to 3 mm in diameter.

(52) After breathing in the fragrance, the composition was applied twice daily morning and evening for up to 12 weeks in a small dose using a spatula, by a smoothing movement from the interior to the exterior of the face and of the neck, which were cleansed beforehand.

(53) The composition used included the compounds indicated in table 1 and 0.03% by weight of oily extract of everlasting, 0.1% by weight of aqueous extract of everlasting, 0.08% by weight of essential oil of everlasting and 2% by weight of aqueous extract of slender-beaded coral weed relative to the total weight of the composition.

(54) TABLE-US-00007 TABLE 7 overall judgment of the composition Immediately after the first application The complexion is illuminated 80% The skin is radiant 89% The skin is supple 94% After 8 weeks of use The complexion is visibly lightened 94% The skin appears luminous 91% The appearance of pigmentation 86% irregularities, such as blackheads, is reduced The size of the pigmentation defects 89% is reduced The complexion is unified 86% The product reduces the appearance of 77% differences in complexion The skin is freed of its dull veil 83% The capacities of the skin to capture 83% and reflect light are increased The skin reveals its clarity 80% The skin regains its natural 94% translucency The skin regains its original light 94% The skin is smoother 100% The skin texture appears refined 100% The irregularities of the skin texture 89% are reduced The skin quality is enhanced or 97% improved The skin uniformity is enhanced or 100% improved The skin appears fairer 94% The skin shines with youthful radiance 83% The skin appears serene 86% The face is illuminated 94% The skin appears more beautiful 94% After 12 weeks of use The complexion is visibly lightened 91% The appearance of pigmentation 80% irregularities, such as blackheads, is reduced The size of the pigmentation defects 89% is reduced The complexion is unified 80% The capacities of the skin to capture 91% and reflect light are increased The skin reveals its clarity 89% The skin regains its natural 94% translucency The skin regains its original light 91% The skin texture appears refined 94% The irregularities of the skin texture 94% are reduced The skin quality is enhanced or 94% improved The skin appears lighter 91% The skin shines with youthful radiance 89% The complexion is harmonious 89% The skin appears free of defects 69% The complexion is visibly lightened 89% The skin appears more beautiful 91%

(55) As demonstrated in table 7, an example of a composition according to some embodiments including 0.03% by weight of oily extract of everlasting, 0.1% by weight of aqueous extract of everlasting, 0.08% by weight of essential oil of everlasting and 2% by weight of aqueous extract of slender-beaded coral weed relative to the total weight of the composition was thus considered as efficient. In particular, as demonstrated, an example of a composition according to some embodiments makes it possible to treat the signs of aging of asiatic skin, especially an enhancement or improvement of the radiance of the complexion, of its homogeneity, of its luminosity, and/or to reduce the skin pigmentation defects. In addition, as demonstrated, an example of a composition according to some embodiments makes it possible to enhance or improve the appearance of the skin, in particular with a more uniform and smoother texture. As demonstrated, the composition advantageously allows treatment immediately after application and over time.

(56) In addition, a visual study of the density of the pigmentation marks and of the radiance of the complexion using the C.L.B.T. score as described in Musnier et al. Visual evaluation in vivo of complexion radiance using the C.L.B.T. sensory methodology. Skin Res Technol. 2004 February; 10(1):50-6 [38] was performed. Each parameter was measured after 2 and 3 months of application of the composition and compared with the measurements taken before the first application of the composition. Thus, an evaluation of the facial skin of the 35 abovementioned volunteers was performed by three trained judges.

(57) The color descriptors, namely Olive, Yellow or Pink, and the physical appearance descriptors, namely the luminosity, brightness and transparency, were defined beforehand. In particular, an increase in the pink color indicated a healthier appearance effect, a decrease in the yellow color indicated a good effect (less yellowish complexion), a decrease in the olive color indicated a good effect and a healthier appearance effect (the complexion is less olive-greenish), an increase in the luminosity: the skin reflects light slightly more intensely, an increase in the luminosity: the complexion has an appearance in terms of texture and color, an increase in transparency: the skin is thinner.

(58) The evaluation was performed in a black room with a controlled temperature and atmosphere (222 C., 5010% hygrometry). After 20 minutes of acclimatization in the controlled room, the individuals were placed between two lamps diffusing daylight.

(59) The complexion was evaluated individually by three trained judges, without knowledge of the data obtained in the preceding stage. The three judges were not permitted to communicate with each other. Evaluation of the three colors was performed using a visual scale of the three main colors of facial skin (olive/yellow/pink). A score was attributed for each color representing a percentage of saturation. Each judge attributed a score for each color at T0, i.e. before treatment.

(60) A Clinical evaluation of the luminosity, brightness and transparency (LBT) was performed by three trained judges. This evaluation was retranscribed on an analog scale extending from 0 (no luminosity/brightness/transparency) to 100 (maximum luminosity/brightness/transparency).

(61) The mean of the scores attributed by the three judges was determined for each of the descriptors.

(62) For the color descriptors, the results were expressed as a percentage of saturation of the color.

(63) For the LBT descriptors, the results were retranscribed by a score ranging from 0 to 10.

(64) Interpretation of the C.L.B.T. results was performed on the basis of the significant variations in the descriptors taken separately:

(65) Statistical analysis of the data: the distribution normality was checked by the Shapiro-Wilk test (1% threshold). Statistical analysis of the change in the measured parameters was performed by the paired bilateral Student t test (in the case of a normal distribution) or of the Wilcoxon test (non-normal distribution). The significance threshold was set at 5%.

(66) Table 8 below summarizes the results obtained:

(67) TABLE-US-00008 Parameters After 2 months After 3 months Density of marks 23% 19% Uniformity of +17% +16% complexion CLBT score Olive color Ns Ns Yellow color 3.9% 6% Pink color Ns Ns Luminosity Ns Ns Clarity +3.7 +6.1 Transparency Ns Ns

(68) As demonstrated in table 8 below, an example of a composition according to some embodiments advantageously makes it possible to reduce the density of pigmentation marks and enhances or improves the uniformity of the complexion. The composition also lightens the complexion (+6.1% at 3 months) and reduces its yellow shade (6% at 3 months). This example thus clearly demonstrates that an example of a composition according to some embodiments is useful and efficient in a cosmetic treatment of aging of the skin.

(69) As demonstrated in this example, the compositions according to some embodiments are effective with various skin phototypes, for example asiatic phototypes.

REFERENCES

(70) 1. Koblenzer C S. Psychologic aspects of aging and the skin. Clinics Dermatol 1996; 14:171-7

(71) 2. West M D. The cellular and molecular biology of skin aging. Arch dermatol 1994; 130:87-95

(72) 3. Grove G L, Kligman A M. Age-associated changes in human epidermal cell renewal. J Gerontol 1983; 38:137-42

(73) 4. Watt F M. Involucrin and other markers of keratinocyte terminal differentiation. J Invest Dermatol. 1983; 81:100s-3s

(74) 5. Mehrel T, Hohl D, Rothnagel J A, Longley M A, Bundman D, Cheng C, Lichti U, Bisher M E, Steven A C, Steinert P M, et al. Identification of a major keratinocyte cell envelope protein, loricrin. Cell. 1990; 61:1103-12

(75) 6. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005; 6:328-40

(76) 7. Watt F M, Green H. Involucrin synthesis is correlated with cell size in human epidermal cultures. J. Cell Biol. 1981; 90:738-742.

(77) 8. Ruhrberg C, Hajibagheri M A, Parry D A, Watt F M. Periplakin, a novel component of cornified envelopes and desmosomes that belongs to the plakin family and forms complexes with envoplakin. J. Cell Biol. 1997; 139:1835-1849.

(78) 9. Ruhrberg C, Hajibagheri M A, Simon M, Dooley T P, Watt F M. Envoplakin, a novel precursor of the cornified envelope that has homology to desmoplakin. J. Cell Biol. 1996; 134:715-729.

(79) 10. DiColandrea T, Karashima T, Maatta A, Watt F M. Subcellular distribution of envoplakin and periplakin: insights into their role as precursors of the epidermal cornified envelope. J. Cell Biol. 2000; 151:573-586.

(80) 11. Sevilla L M, Nachat R, Groot K R, Klement J F, Uitto J, Djian P, Maatta A, Watt F M., Mice deficient in involucrin, envoplakin, and periplakin have a defective epidermal barrier. J. Cell Biol. 2007; 179:1599-1612.

(81) 12. Kalinin A, Marekov L N, Steinert P M. Assembly of the epidermal cornified cell envelope. J. Cell Sci. 2001; 114:3069-3070.

(82) 13. Eckert R L, Sturniolo M T, Broome A M, Ruse M, Rorke E A. Transglutaminase function in epidermis. J. Invest. Dermatol. 2005; 124:481-492.

(83) 14. Steinert P M, Marekov L N. Initiation of assembly of the cell envelope barrier structure of stratified squamous epithelia. Mol. Biol. Cell 1999; 10:4247-4261.

(84) 15. Ahvazi B, Boeshans K M, Idler W, Baxa U, Steinert P M. Roles of calcium ions in the activation and activity of the transglutaminase 3 enzyme. J. Biol. Chem. 2003; 278:23834-23841.

(85) 16. Jackson B, Tilli C M, Hardman M J, Avilion A A, MacLeod M C, Ashcroft G S, Byrne C. Late cornified envelope family in differentiating epitheliaresponse to calcium and ultraviolet irradiation. J. Invest. Dermatol. 2005; 124:1062-1070.

(86) 17. Marshall D, Hardman M J, Nield K M, Byrne C. Differentially expressed late constituents of the epidermal cornified envelope. Proc. Natl. Acad. Sci. U.S.A. 2001; 98:13031-13036.

(87) 18. Denda M, Tomitaka A, Akamatsu H, Matsunaga K. Altered distribution of calcium in facial epidermis of aged adults. J. Invest. Dermatol. 2003; 121:1557-1558.

(88) 19. Chavanas S, Mchin M C, Nachat R, Adoue V, Coudane F, Serre G, Simon M. Peptidylarginine deiminases and deimination in biology and pathology: relevance to skin homeostasis. J Dermatol Sci. 2006; 44:63-72.

(89) 20. Denecker G, Ovaere P, Vandenabeele P, Declercq W. Caspase-14 reveals its secrets. J Cell Biol. 2008; 180:451-8.

(90) 21. Brown S J, McLean W H. One remarkable molecule: filaggrin. J Invest Dermatol. 2012; 132:751-62.

(91) 22. Steinert P M, Cantieri J S, Teller D C, Lonsdale-Eccles J D, Dale B A. Characterization of a class of cationic proteins that specifically interact with intermediate filaments. Proc Natl Acad Sci USA. 1981 July; 78(7):4097-101.

(92) 23. Rawlings A V, Harding C R. Moisturization and skin barrier function. Dermatol Ther. 2004; 17 Suppl 1:43-8.

(93) 24. Elias P M, Steinhoff M. Outside-to-inside (and now back to outside) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008 May; 128(5):1067-70.

(94) 25. FR3000389

(95) 26. FR0111224

(96) 27. FR0605953

(97) 28. FR0905904

(98) 29. FR1153960

(99) 30. Farid Chemat: Eco-extraction du vgtal, Editions Dunod, 2011.

(100) 31. BENAISSI, K. Le CO2 supercritique appliqu l'extraction vgtale. Techniques de l'ingnieur Dveloppement de solvants alternatifs et intensification des procds. 2013. http://www.techniques-ingenieur.fr/

(101) 32. http://www.chem.agilent.com/library/usermanuals/Public/G4140-90040_GeneExpression_OneColor_6.6.pdf

(102) 33. Bejamini Y & Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B. 1995; 57:289-300.

(103) 34. Wu Z, Hansmann B, Meyer-Hoffert U, Glser R, Schrder J M. Molecular identification and expression analysis of filaggrin-2, a member of the S100 fused-type protein family. PLoS One. 2009; 4:e5227

(104) 35. La Celle P T, Polakowska R R. Human homeobox HOXA7 regulates keratinocyte transglutaminase type 1 and inhibits differentiation. J Biol Chem. 2001; 276:32844-53

(105) 36. Segre J A, Bauer C, Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. Nat Genet. 1999; 22:356-60

(106) 37. Sato C, Tsuboi R, Shi C M, Rubin J S, Ogawa H. Comparative study of hepatocyte growth factor/scatter factor and keratinocyte growth factor effects on human keratinocytes. J Invest Dermatol. 1995; 104:958-63

(107) 38. Musnier C, Piquemal P, Beau P, Pittet J C. Visual evaluation in vivo of complexion radiance using the C.L.B.T. sensory methodology. Skin Res Technol. 2004 February; 10(1):50-6.